Kara Yakhteh Tajhiz Azma Company, which is engaged in the production and characterization of engineered lymphocytes with specific nanobody-containing chimeric receptors for use in immunotherapy, as well as the production of cancer vaccines for pediatric patients, has recently joined the Hitco Group.
This project, supported by the Vice Presidency for Science and Technology of the Presidency, has entered the operational phase. It is located at the Comprehensive Center for Stem Cells and Regenerative Medicine and operates with a gene therapy section within the clean rooms of the Comprehensive Laboratory Research Building at Tehran University of Medical Sciences. The initiative aims to advance its objectives and reach the implementation phase.
